Marti Technologies, Inc. (MRT)

Marti Technologies: Buy The Inflection Point

Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer

Marti Technologies, Inc. (MRT) Q2 2026 Earnings Call Transcript

Marti Technologies H1 Earnings Call Highlights

Marti Achieves Record Second Quarter with 141% Revenue Growth, 77% Gross Profit Margin, Significant Improvement in Profitability, and Increased Guidance

Marti Technologies, Inc. to Report 2026 Second Quarter Results on August 19, 2026

Marti Technologies Launches Ride-Hailing Service in 10 New Cities Across Türkiye

Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Marti Technologies Increases Fiscal Year 2026 Guidance on Accelerating Growth and Margin Expansion

Marti and Tensor Partner to Deploy Autonomous Vehicles in Türkiye

Marti Technologies Provides Update on Its Share Repurchase Program

Marti's Ride-Hailing Service Reaches 4.30 Million Riders and 532 Thousand Registered Drivers, Exceeding June 30, 2026 Targets

Marti Is Highly Risky, Financially And Operationally